Abstract:Background and purpose: The pathophysiological features of acute ischemic stroke (AIS) often involve dysfunction of the blood-brain barrier (BBB), characterized by the degradation of tight junction proteins (Tjs) leading to increased permeability. This dysfunction can exacerbate cerebral injury and contribute to severe complications. The permeability of the BBB fluctuates during different stages of AIS and is influenced by various factors. Developing effective therapies to restore BBB function remains a significant challenge in AIS treatment. High levels of vascular endothelial growth factor (VEGF) in the early stages of AIS have been shown to worsen BBB breakdown and stroke progression. Our study aimed to investigate the protective effects of the VEGF receptor inhibitor Axitinib on BBB dysfunction and cerebral ischemia/reperfusion-induced injury. Methods: BEnd3 cell exposed to oxygen-glucose deprivation (OGD) model was constructed to estimate pharmacological activity of Axitinib (400 ng/ml) on anti-apoptosis and pathological barrier function recovery. In vivo, rats were subjected to a 1 h transient middle cerebral artery occlusion and 23 h reperfusion (tMCAO/R) to investigate the permeability of BBB and cerebral tissue damage. Axitinib was administered through the tail vein at the beginning of reperfusion. BBB integrity was assessed by Evans blue leakage and the expression levels of Tjs claudin-5 and occludin. Results: Our research revealed that co-incubation with Axitinib enhanced the cell viability of OGD-insulted bEnd3 cells, decreased LDH leakage rate, and suppressed the expression of apoptosis-related proteins cytochrome C and Bax. Axitinib also mitigated the damage to Tjs and facilitated the restoration of transepithelial electrical resistance in OGD-insulted bEnd.3 cells. In vivo, Axitinib administration reduced intracerebral Evans blue leakage and up-regulated the expression of Tjs in the penumbra brain tissue in tMCAO/R rats. Notably, 10 mg/kg Axitinib exerted a significant anti-ischemic effect by decreasing cerebral infarct volume and brain edema volume, improving neurological function, and reducing pro-inflammatory cytokines IL-6 and TNF-alpha in the brain. Conclusions: Our study highlights Axitinib as a potent protectant of blood-brain barrier function, capable of promoting pathological blood-brain barrier recovery through VEGF inhibition and increased expression of tight junction proteins in AIS. This suggests that VEGF antagonism within the first 24 h post-stroke could be a novel therapeutic approach to enhance blood-brain barrier function and mitigate ischemia-reperfusion injury.

Lithium alleviates blood-brain barrier breakdown after cerebral ischemia and reperfusion by upregulating endothelial Wnt/β-catenin signaling in mice

Lithium attenuates blood–brain barrier damage and brain edema following intracerebral hemorrhage via an endothelial Wnt/β‐catenin signaling‐dependent mechanism in mice

Lithium enhances post-stroke blood-brain barrier integrity, activates the MAPK/ERK1/2 pathway and alters immune cell migration in mice

Lithium Treatment Mitigates White Matter Injury after Intracerebral Hemorrhage Through Brain-Derived Neurotrophic Factor Signaling in Mice

Lithium Improves the Behavioral Disorder in Rats Subjected to Transient Global Cerebral Ischemia.

Lithium upregulates growth-associated protein-43 (GAP-43) and postsynaptic density-95 (PSD-95) in cultured neurons exposed to oxygen-glucose deprivation and improves electrophysiological outcomes in rats subjected to transient focal cerebral ischemia following a long-term recovery period

Lithium-induced Activation of Akt and CaM Kinase II Contributes to Its Neuroprotective Action in a Rat Microsphere Embolism Model.

Lithium Chloride Contributes to Blood Spinal Cord Barrier Integrity and Functional Recovery from Spinal Cord Injury by Stimulating Autophagic Flux

The neuroprotective mechanism of lithium after ischaemic stroke

Inhibiting Endoplasmic Reticulum Stress by Lithium Chloride Contributes to the Integrity of Blood-Spinal Cord Barrier and Functional Recovery after Spinal Cord Injury.

Exploring the Neuroprotective Effects of Lithium in Ischemic Stroke: A literature review

Lithium Regulates Hippocampal Neurogenesis by ERK Pathway and Facilitates Recovery of Spatial Learning and Memory in Rats after Transient Global Cerebral Ischemia

The Protective Effects of Axitinib on Blood-Brain Barrier Dysfunction and Ischemia-Reperfusion Injury in Acute Ischemic Stroke

Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity.

Neuroprotective Effects of Magnesium Lithospermate B Against Subarachnoid Hemorrhage in Rats

Enhancement of neuroprotection and heat shock protein induction by combined prostaglandin A1 and lithium in rodent models of focal ischemia.

Synergistic Effects of Prostaglandin E1 and Lithium in a Rat Model of Cerebral Ischemia

Lithium Exacerbates Hepatic Ischemia/reperfusion Injury by Inhibiting GSK-3β/NF-κB-mediated Protective Signaling in Mice.

Lomitapide Ameliorates Middle Cerebral Artery Occlusion-Induced Cerebral Ischemia/reperfusion Injury by Promoting Neuronal Autophagy and Inhibiting Microglial Migration.

Lithium Suppressed Tyr-402 Phosphorylation of Proline-Rich Tyrosine Kinase (pyk2) and Interactions of Pyk2 and PSD-95 with NR2A in Rat Hippocampus Following Cerebral Ischemia.

Pulmonary , gastrointestinal and urogenital pharmacology Lithium exacerbates hepatic ischemia / reperfusion injury by inhibiting GSK-3 b / NFk B-mediated protective signaling in mice